|
|
SciMed -
Healthcare
|
|
TS-Si News Service
|
|
Monday, 01 May 2006 04:32 |
Washington, DC, USA. Thousands of women who rely on custom-made  hormone drugs for relief from menopause symptoms have flooded the government with letters opposing a drug company's effort to get health officials to crack down on pharmacies that sell them. The drug company Wyeth wants the Food and Drug Administration to rein in the market for bio-identical hormone-replacement therapy drugs. The hormones are custom mixed or compounded by specialized pharmacies according to a doctor's prescription.
|
|
Last Updated on Tuesday, 11 September 2007 09:33 |
|
|
SciMed -
Healthcare
|
|
TS-Si News Service
|
|
Thursday, 27 April 2006 02:58 |
|
Tucson, Arizona, USA. Calamity, a horse, was rescued from a farm that harvests urine from pregnant mares to make Premarin, used widely as a hormone replacement therapy drug.
The website equinevoices.org has placed the 5 year old mare at sale for $1,400 and has other horses available for adoption.
|
|
Last Updated on Monday, 27 August 2007 15:58 |
|
SciMed -
Healthcare
|
|
TS-Si News Service
|
|
Wednesday, 26 April 2006 19:00 |
|
Results May Help Doctors Understand Both TS & Natal Women
Washington, DC, USA. In 2002, medical researchers found estrogen and progestin, usually sold in combination as Prempro, increased breast cancer risk by 26 percent.
 Maybe that is not the case. A new study shows one form of estrogen therapy used to ease menopause symptoms could be far less dangerous than feared. Results show estrogen alone, usually given to women who have had hysterectomies, does not increase risk for breast cancer.
It is the first promising news on hormone replacement therapy since the giant women's health initiative was stopped in 2002. Then, it found the combination of estrogen and progestin, usually sold as Prempro, increased breast cancer risk by 26-percent.
The findings have a direct impact on transsexual women. TS women are often mistreated by doctors as equivalent to post-menopausal women.
While doctors say that hormone therapy has a complex set of risks and benefits that need to be considered individually for every patent, their advice often fails to account for the situation faced by transsexual women.
Those who headed up that study, say women and their doctors assumed all hormones had the same danger. "The problem is that we keep using 'hormones' and we're not distinguishing between these two very different treatment options for different kinds of women," says Hormone Replacement Specialist Dr. Marcia Stefanick.
However, estrogen alone does increase the risk of uterine cancer, and is not usually given to women unless they have had hysterectomies.
|
|
Last Updated on Monday, 03 December 2007 15:03 |
|
|
SciMed -
Healthcare
|
|
TS-Si News Service
|
|
Friday, 21 April 2006 13:08 |
|
Beneficiaries Face Increases Next Year
The six million poorest beneficiaries may pay as much as seven percent more next year for the new U.S. Medicare prescription drug benefit.
While these beneficiaries have no annual co-payment and don't have to contend with a coverage gap, their co-payments for generic drugs will increase from $2 to $2.15 and from $5 to $5.35 for brand-name drugs, the Los Angeles Times reported.
These increases may seem small, but many state-sponsored Medicaid plans previously charged no co-payments. These Medicare co-payments may prove too much of a burden for low-income people who require 10 or more prescription drugs, say independent experts and state officials.
These and other cost increases were included when the new prescription drug plan was designed, the Times reported. Congress decided to index the share paid by beneficiaries to yearly increases in prescription drug spending.
|
|
Last Updated on Monday, 27 August 2007 16:00 |
|
SciMed -
Healthcare
|
|
TS-Si News Service
|
|
Friday, 21 April 2006 12:59 |
Wants Intervention Against Drug Compounders
Drug maker Wyeth is demanding that the U.S. Food and Drug Administration crack down on specialized compounding pharmacies that make custom-made hormone drugs to treat menopause. The drugs are made according to a doctor's prescription.
In response to Wyeth's request to the FDA, thousands of women who use the custom-made treatments have deluged the agency with letters opposing any move against compounding pharmacies, the Associated Press reported.
Many women turned to the products sold by compounding pharmacies after a 2002 federal study found that replacement hormones -- HRT -- made by drug companies increased the risk of heart attacks, strokes and breast cancer, the news service said.
Wyeth charges that some compounding pharmacies dupe women with products that may pose serious health risks. It wants the FDA to use seizures, injunctions, and warning letters to go after these pharmacies, the AP reported.
The custom-made estrogen, progesterone and testosterone products sold by compounding pharmacies are not FDA-approved. The FDA said it needs more time to review and respond to Wyeth's petition and the 27,000 comments about it.
|
|
Last Updated on Monday, 27 August 2007 15:59 |
|
|
|
|
<< Start < Prev 51 52 53 54 55 56 57 Next > End >>
|
|
Page 56 of 57 |
The TS-Si News Service
and the TS-Si Research Service are collaborations of TS-Si officials, staff, contributors, and corresponding institutions. The contents do not necessarily convey official positions of TS-Si or its owners, participants, partners, or affiliates.